{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T18:39:56Z","timestamp":1792435196194,"version":"4.5.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T00:00:00Z","timestamp":1792368000000},"content-version":"vor","delay-in-days":96,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Shanghai Pudong New Area Science and Technology Development Fund for the People\u2019s Livelihood Research Project","award":["PKJ2023-Y43"],"award-info":[{"award-number":["PKJ2023-Y43"]}]},{"name":"Shanghai Pudong New Area Science and Technology Development Fund for the People\u2019s Livelihood Research Project","award":["PKJ2024-Y59"],"award-info":[{"award-number":["PKJ2024-Y59"]}]},{"name":"Shanghai Pudong New Area Health Commission Funds","award":["PW2023A-10"],"award-info":[{"award-number":["PW2023A-10"]}]},{"name":"Shanghai Municipal Health Commission Funds","award":["202240052"],"award-info":[{"award-number":["202240052"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Thoracic bone and soft tissue sarcoma (BSTS) represents a rare malignancy. For patients with medically inoperable BSTS, radiotherapy (RT) is a recommended treatment modality. Carbon ion radiotherapy (CIRT) has shown superior efficacy compared to photon-based RT. However, data on the use of CIRT for thoracic BSTS remain scarce. This study aimed to evaluate the clinical outcomes and toxicity profile of CIRT in patients with thoracic BSTS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The inclusion criteria were as follows: 1)\u2009\u2265\u200914 years old; 2) primary or metastatic BSTS in chest area, with histologically confirmed primary tumor; 3) with visible lesion; 4) definitive CIRT intent; and 5) had at least one follow-up, and the time between follow-up and the first fraction of CIRT was longer than 1 month. The prescribed CIRT doses ranged from 59.5 to 80\u00a0Gy (RBE) delivered in 10\u201323 fractions. Treatment-related toxicities were assessed using the Common Terminology Criteria for Adverse Events Version 4.03, while tumor response was evaluated according to the Response Evaluation Criteria in Solid Tumors Version 1.1. Local control (LC), progression-free survival (PFS), and overall survival (OS) rates were estimated using the Kaplan-Meier method. Subgroup analyses were performed using the Log-rank test.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 33 patients with 35 lesions were included in the study. The median age of the cohort was 56 years (range: 22\u201386 years), with a median follow-up duration of 42.1 months (range: 3.8\u2013100.6 months). The 3-year LC rates for the entire cohort were 85.2%. There was no statistically significant difference in LC when categorized by median tumor volume and biological effective dose. The use of simultaneous integrated boost technology appears to improve the LC. Among patients with primary thoracic BSTS, the 3-year LC, PFS\uff0c and OS rates were 84%, 54.8%\uff0c and 76.7%, respectively. Patients with postoperative recurrence (PORC) demonstrated significantly inferior PFS and OS. Except one case of grade 3 chest wall pain and 1 brachial plexopathy, no grade\u2009\u2265\u20093 toxicities were observed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>CIRT is safe and effective in the management of thoracic BSTS. Further studies with more cases and longer observation periods are warranted.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>\n                      Retrospectively registered on 13th February, 2026; ChiCTR2600118943; Chinese Clinical Trial Registry;\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/www.chictr.org.cn\/bin\/project\/edit?pid=308155\" ext-link-type=\"uri\">https:\/\/www.chictr.org.cn\/bin\/project\/edit?pid=308155<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-026-16541-x","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T05:14:24Z","timestamp":1784092464000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Definitive carbon ion radiotherapy for thoracic bone and soft tissue sarcoma"],"prefix":"10.1186","volume":"26","author":[{"given":"Jian","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ningyi","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaqi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai-Liang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingfang","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,15]]},"reference":[{"issue":"12","key":"16541_CR1","doi-asserted-by":"publisher","first-page":"2689","DOI":"10.1016\/j.ejca.2013.04.007","volume":"49","author":"L Duranti","year":"2013","unstructured":"Duranti L, Gronchi A, Stacchiotti S, Fiore M, Casali PG, Collini P, Pelosi G, Galeone C, Pastorino U. Localised thoracic sarcomas: outcome improvement over time at a single institution. Eur J Cancer. 2013;49(12):2689\u201397.","journal-title":"Eur J Cancer"},{"key":"16541_CR2","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.radonc.2022.05.020","volume":"173","author":"B Allignet","year":"2022","unstructured":"Allignet B, Waissi W, Geets X, Dufresne A, Brahmi M, Ray-Coquard I, Blay JY, Bouhamama A, Meeus P, Vaz G, et al. Long-term outcomes after definitive radiotherapy with modern techniques for unresectable soft tissue sarcoma. Radiotherapy oncology: J Eur Soc Therapeutic Radiol Oncol. 2022;173:55\u201361.","journal-title":"Radiotherapy oncology: J Eur Soc Therapeutic Radiol Oncol"},{"issue":"1","key":"16541_CR3","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/S0360-3016(00)00568-X","volume":"48","author":"M Suzuki","year":"2000","unstructured":"Suzuki M, Kase Y, Yamaguchi H, Kanai T, Ando K. Relative biological effectiveness for cell-killing effect on various human cell lines irradiated with heavy-ion medical accelerator in Chiba (HIMAC) carbon-ion beams. Int J Radiat Oncol Biol Phys. 2000;48(1):241\u201350.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"9","key":"16541_CR4","doi-asserted-by":"publisher","first-page":"4308","DOI":"10.1002\/cam4.1679","volume":"7","author":"R Imai","year":"2018","unstructured":"Imai R, Kamada T, Araki N. Working Group for Carbon Ion Radiotherapy for B, Soft Tissue S: Carbon ion radiotherapy for unresectable localized axial soft tissue sarcoma. Cancer Med. 2018;7(9):4308\u201314.","journal-title":"Cancer Med"},{"issue":"4","key":"16541_CR5","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1016\/j.ijrobp.2008.12.019","volume":"75","author":"I Serizawa","year":"2009","unstructured":"Serizawa I, Kagei K, Kamada T, Imai R, Sugahara S, Okada T, Tsuji H, Ito H, Tsujii H. Carbon ion radiotherapy for unresectable retroperitoneal sarcomas. Int J Radiat Oncol Biol Phys. 2009;75(4):1105\u201310.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"16541_CR6","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1186\/s12885-021-08493-1","volume":"21","author":"J Chen","year":"2021","unstructured":"Chen J, Mao J, Ma N, Wu KL, Lu J, Jiang GL. Definitive carbon ion radiotherapy for tracheobronchial adenoid cystic carcinoma: a preliminary report. BMC Cancer. 2021;21(1):734.","journal-title":"BMC Cancer"},{"issue":"1","key":"16541_CR7","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s13014-019-1216-1","volume":"14","author":"J Chen","year":"2019","unstructured":"Chen J, Lu JJ, Ma N, Zhao J, Chen C, Fan M, Jiang G, Mao J. Early stage non-small cell lung cancer treated with pencil beam scanning particle therapy: retrospective analysis of early results on safety and efficacy. Radiat Oncol. 2019;14(1):16.","journal-title":"Radiat Oncol"},{"issue":"2","key":"16541_CR8","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.ijrobp.2013.01.032","volume":"86","author":"H Bahig","year":"2013","unstructured":"Bahig H, Roberge D, Bosch W, Levin W, Petersen I, Haddock M, Freeman C, Delaney TF, Abrams RA, Indelicato DJ, et al. Agreement among RTOG sarcoma radiation oncologists in contouring suspicious peritumoral edema for preoperative radiation therapy of soft tissue sarcoma of the extremity. Int J Radiat Oncol Biol Phys. 2013;86(2):298\u2013303.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"9325","key":"16541_CR9","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1016\/S0140-6736(02)09292-9","volume":"359","author":"B O\u2019Sullivan","year":"2002","unstructured":"O\u2019Sullivan B, Davis AM, Turcotte R, Bell R, Catton C, Chabot P, Wunder J, Kandel R, Goddard K, Sadura A, et al. Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: a randomised trial. Lancet. 2002;359(9325):2235\u201341.","journal-title":"Lancet"},{"issue":"20","key":"16541_CR10","doi-asserted-by":"publisher","first-page":"3159","DOI":"10.1002\/cncr.28845","volume":"120","author":"AM van Maldegem","year":"2014","unstructured":"van Maldegem AM, Gelderblom H, Palmerini E, Dijkstra SD, Gambarotti M, Ruggieri P, Nout RA, van de Sande MA, Ferrari C, Ferrari S, et al. Outcome of advanced, unresectable conventional central chondrosarcoma. Cancer. 2014;120(20):3159\u201364.","journal-title":"Cancer"},{"issue":"10","key":"16541_CR11","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1016\/0360-3016(86)90312-3","volume":"12","author":"JD Slater","year":"1986","unstructured":"Slater JD, McNeese MD, Peters LJ. Radiation therapy for unresectable soft tissue sarcomas. Int J Radiat Oncol Biol Phys. 1986;12(10):1729\u201334.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"16541_CR12","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1016\/j.ijrobp.2005.03.004","volume":"63","author":"L Kepka","year":"2005","unstructured":"Kepka L, DeLaney TF, Suit HD, Goldberg SI. Results of radiation therapy for unresected soft-tissue sarcomas. Int J Radiat Oncol Biol Phys. 2005;63(3):852\u20139.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"16541_CR13","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/j.ijrobp.2022.05.017","volume":"114","author":"PM Gutkin","year":"2022","unstructured":"Gutkin PM, von Eyben R, Chin A, Donaldson SS, Oh J, Jiang A, Ganjoo KN, Avedian RS, Bruzoni M, Steffner RJ, et al. Local Control Outcomes Using Stereotactic Body Radiation Therapy or Surgical Resection for Metastatic Sarcoma. Int J Radiat Oncol Biol Phys. 2022;114(4):771\u20139.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"16541_CR14","doi-asserted-by":"publisher","first-page":"E17","DOI":"10.3171\/2021.2.FOCUS201059","volume":"50","author":"Z Pennington","year":"2021","unstructured":"Pennington Z, Ehresman J, Elsamadicy AA, Shin JH, Goodwin CR, Schwab JH, Sciubba DM. Systematic review of charged-particle therapy for chordomas and sarcomas of the mobile spine and sacrum. Neurosurg Focus. 2021;50(5):E17.","journal-title":"Neurosurg Focus"},{"issue":"19","key":"16541_CR15","doi-asserted-by":"publisher","first-page":"3496","DOI":"10.1002\/cncr.28177","volume":"119","author":"K Matsumoto","year":"2013","unstructured":"Matsumoto K, Imai R, Kamada T, Maruyama K, Tsuji H, Tsujii H, Shioyama Y, Honda H, Isu K, Working Group for B. Impact of carbon ion radiotherapy for primary spinal sarcoma. Cancer. 2013;119(19):3496\u2013503.","journal-title":"Cancer"},{"issue":"12","key":"16541_CR16","first-page":"6959","volume":"37","author":"R Imai","year":"2017","unstructured":"Imai R, Kamada T, Araki N, Working Group For B, Soft-Tissue S. Clinical Efficacy of Carbon Ion Radiotherapy for Unresectable Chondrosarcomas. Anticancer Res. 2017;37(12):6959\u201364.","journal-title":"Anticancer Res"},{"issue":"7","key":"16541_CR17","doi-asserted-by":"publisher","first-page":"e70840","DOI":"10.1002\/cam4.70840","volume":"14","author":"M Varnava","year":"2025","unstructured":"Varnava M, Tashiro M, Okamoto M, Ando K, Kubo N, Kawamura H, Onishi M, Shibuya K, Kumazawa T, Ohtaka T, et al. Dose-Volume Constraints for Thoracic, Abdominal, and Pelvic Carbon Ion Radiotherapy: A Literature Review. Cancer Med. 2025;14(7):e70840.","journal-title":"Cancer Med"},{"key":"16541_CR18","doi-asserted-by":"publisher","first-page":"666141","DOI":"10.3389\/fonc.2021.666141","volume":"11","author":"J Zhao","year":"2021","unstructured":"Zhao J, Chen Z, Wu X, Xing Y, Li Y. Study of an Online Plan Verification Method and the Sensitivity of Plan Delivery Accuracy to Different Beam Parameter Errors in Proton and Carbon Ion Radiotherapy. Front Oncol. 2021;11:666141.","journal-title":"Front Oncol"},{"issue":"2","key":"16541_CR19","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1002\/pro6.1232","volume":"8","author":"K Wang","year":"2024","unstructured":"Wang K, Yuan S. Current status and prospect of particle therapy for esophageal cancer. Precis Radiat Oncol. 2024;8(2):92\u20138.","journal-title":"Precis Radiat Oncol"},{"issue":"6","key":"16541_CR20","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1016\/j.ejso.2022.02.016","volume":"49","author":"M Baia","year":"2023","unstructured":"Baia M, Ford SJ, Dumitra S, Sama L, Naumann DN, Spolverato G, Callegaro D. Follow-up of patients with retroperitoneal sarcoma. Eur J Surg Oncol. 2023;49(6):1125\u201332.","journal-title":"Eur J Surg Oncol"},{"issue":"3","key":"16541_CR21","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1097\/SLA.0b013e3181cf87fa","volume":"251","author":"A Gronchi","year":"2010","unstructured":"Gronchi A, Lo Vullo S, Colombo C, Collini P, Stacchiotti S, Mariani L, Fiore M, Casali PG. Extremity soft tissue sarcoma in a series of patients treated at a single institution: local control directly impacts survival. Ann Surg. 2010;251(3):506\u201311.","journal-title":"Ann Surg"},{"issue":"5","key":"16541_CR22","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1016\/j.ijrobp.2010.08.043","volume":"82","author":"K Jingu","year":"2012","unstructured":"Jingu K, Tsujii H, Mizoe JE, Hasegawa A, Bessho H, Takagi R, Morikawa T, Tonogi M, Tsuji H, Kamada T, et al. Carbon ion radiation therapy improves the prognosis of unresectable adult bone and soft-tissue sarcoma of the head and neck. Int J Radiat Oncol Biol Phys. 2012;82(5):2125\u201331.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"16541_CR23","doi-asserted-by":"crossref","unstructured":"Shiba S, Okamoto M, Kiyohara H, Okazaki S, Kaminuma T, Shibuya K, Kohama I, Saito K, Yanagawa T, Chikuda H et al. Impact of Carbon Ion Radiotherapy on Inoperable Bone Sarcoma. Cancers (Basel). 2021;13(5):1099.","DOI":"10.3390\/cancers13051099"},{"issue":"5","key":"16541_CR24","doi-asserted-by":"publisher","first-page":"2853","DOI":"10.21873\/anticanres.14260","volume":"40","author":"F Cuccia","year":"2020","unstructured":"Cuccia F, Fiore MR, Barcellini A, Iannalfi A, Vischioni B, Ronchi S, Bonora M, Riva G, Vai A, Facoetti A, et al. Outcome and Toxicity of Carbon Ion Radiotherapy for Axial Bone and Soft Tissue Sarcomas. Anticancer Res. 2020;40(5):2853\u20139.","journal-title":"Anticancer Res"},{"key":"16541_CR25","first-page":"100864","volume":"49","author":"H Kubota","year":"2024","unstructured":"Kubota H, Demizu Y, Iwashita K, Fukumitsu N, Takahashi D, Park S, Tsuruoka S, Matsuo Y, Terashima K, Tokumaru S, et al. Definitive particle therapy using protons or carbon ions for dedifferentiated liposarcoma. Clin Transl Radiat Oncol. 2024;49:100864.","journal-title":"Clin Transl Radiat Oncol"},{"issue":"6","key":"16541_CR26","doi-asserted-by":"publisher","first-page":"e14279","DOI":"10.1002\/acm2.14279","volume":"25","author":"W Wang","year":"2024","unstructured":"Wang W, Sun J, Zhao J, Cheng J, Jiang GL, Wang Z. Up modulation of dose-averaged linear energy transfer by simultaneous integrated boost in carbon-ion radiotherapy for pancreatic carcinoma. J Appl Clin Med Phys. 2024;25(6):e14279.","journal-title":"J Appl Clin Med Phys"},{"key":"16541_CR27","doi-asserted-by":"publisher","first-page":"110584","DOI":"10.1016\/j.radonc.2024.110584","volume":"201","author":"G Li","year":"2024","unstructured":"Li G, Ma N, Wang W, Chen J, Mao J, Jiang G, Wu K. Dose-averaged linear energy transfer within the gross tumor volume of non-small-cell lung cancer affects the local control in carbon-ion radiotherapy. Radiotherapy oncology: J Eur Soc Therapeutic Radiol Oncol. 2024;201:110584.","journal-title":"Radiotherapy oncology: J Eur Soc Therapeutic Radiol Oncol"},{"key":"16541_CR28","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.3389\/fonc.2020.01368","volume":"10","author":"J Yang","year":"2020","unstructured":"Yang J, Hu W, Guan X, Hu J, Gao J, Qiu X, Huang Q, Zhang W, Kong L, Lu JJ. Particle Beam Radiation Therapy for Skull Base Sarcomas. Front Oncol. 2020;10:1368.","journal-title":"Front Oncol"},{"issue":"2","key":"16541_CR29","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1097\/01.SLA.0000048448.56448.70","volume":"237","author":"FC Eilber","year":"2003","unstructured":"Eilber FC, Rosen G, Nelson SD, Selch M, Dorey F, Eckardt J, Eilber FR. High-grade extremity soft tissue sarcomas: factors predictive of local recurrence and its effect on morbidity and mortality. Ann Surg. 2003;237(2):218\u201326.","journal-title":"Ann Surg"},{"issue":"20","key":"16541_CR30","doi-asserted-by":"publisher","first-page":"e151","DOI":"10.2106\/JBJS.L.01149","volume":"95","author":"BK Potter","year":"2013","unstructured":"Potter BK, Hwang PF, Forsberg JA, Hampton CB, Graybill JC, Peoples GE, Stojadinovic A. Impact of margin status and local recurrence on soft-tissue sarcoma outcomes. J Bone Joint Surg Am. 2013;95(20):e151.","journal-title":"J Bone Joint Surg Am"},{"issue":"8","key":"16541_CR31","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1002\/1097-0142(19910415)67:8<2083::AID-CNCR2820670813>3.0.CO;2-5","volume":"67","author":"P Gustafson","year":"1991","unstructured":"Gustafson P, Rooser B, Rydholm A. Is local recurrence of minor importance for metastases in soft tissue sarcoma? Cancer. 1991;67(8):2083\u20136.","journal-title":"Cancer"},{"issue":"3","key":"16541_CR32","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1200\/JCO.1985.3.3.353","volume":"3","author":"DA Potter","year":"1985","unstructured":"Potter DA, Glenn J, Kinsella T, Glatstein E, Lack EE, Restrepo C, White DE, Seipp CA, Wesley R, Rosenberg SA. Patterns of recurrence in patients with high-grade soft-tissue sarcomas. J Clin oncology: official J Am Soc Clin Oncol. 1985;3(3):353\u201366.","journal-title":"J Clin oncology: official J Am Soc Clin Oncol"},{"key":"16541_CR33","doi-asserted-by":"crossref","unstructured":"Tsuchie H, Emori M, Murahashi Y, Mizushima E, Shimizu J, Nagasawa H, Miyakoshi N, Murata S, Teramoto A. Detailed Analysis of Prognostic Factors in Patients with Soft Tissue Sarcoma Undergoing Unplanned Excision. Med Princ Pract. 2025;34(6):593\u2013601.","DOI":"10.1159\/000547333"},{"issue":"6","key":"16541_CR34","doi-asserted-by":"publisher","first-page":"2634","DOI":"10.21873\/invivo.13371","volume":"37","author":"T Iwai","year":"2023","unstructured":"Iwai T, Hoshi M, Oebisu N, Takada N, Ban Y, Yao H, Nakamura H. Optimal Prognostic Factors for Metastatic and Inoperable Sarcomas Treated With Pazopanib, Eribulin, and Trabectedin. Vivo. 2023;37(6):2634\u201341.","journal-title":"Vivo"},{"key":"16541_CR35","doi-asserted-by":"crossref","unstructured":"Schwartz PB, Vande Walle K, Winslow ER, Ethun CG, Tran TB, Poultsides G, Tseng J, Roggin K, Grignol V, Howard JH et al. Predictors of Disease-Free and Overall Survival in Retroperitoneal Sarcomas: A Modern 16-Year Multi-Institutional Study from the United States Sarcoma Collaboration (USSC). Sarcoma. 2019;2019:5395131.","DOI":"10.1155\/2019\/5395131"},{"issue":"1","key":"16541_CR36","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1667\/RADE-20-00226.1","volume":"196","author":"RL Haas","year":"2021","unstructured":"Haas RL, Floot BGJ, Scholten AN, van der Graaf WTA, van Houdt W, Schrage Y, van de Ven M, Bovee J, van Coevorden F, Vens C. Cellular Radiosensitivity of Soft Tissue Sarcoma. Radiat Res. 2021;196(1):23\u201330.","journal-title":"Radiat Res"},{"issue":"14","key":"16541_CR37","doi-asserted-by":"publisher","first-page":"3265","DOI":"10.1002\/cncr.32921","volume":"126","author":"AJ Bishop","year":"2020","unstructured":"Bishop AJ, Landry JP, Roland CL, Ratan R, Feig BW, Moon BS, Zarzour MA, Wang WL, Lazar AJ, Lewis VO, et al. Certain risk factors for patients with desmoid tumors warrant reconsideration of local therapy strategies. Cancer. 2020;126(14):3265\u201373.","journal-title":"Cancer"},{"issue":"10","key":"16541_CR38","doi-asserted-by":"publisher","first-page":"2672","DOI":"10.1093\/annonc\/mdt254","volume":"24","author":"RB Keus","year":"2013","unstructured":"Keus RB, Nout RA, Blay JY, de Jong JM, Hennig I, Saran F, Hartmann JT, Sunyach MP, Gwyther SJ, Ouali M, et al. Results of a phase II pilot study of moderate dose radiotherapy for inoperable desmoid-type fibromatosis\u2013an EORTC STBSG and ROG study (EORTC 62991\u2009\u2013\u200922998). Ann Oncol. 2013;24(10):2672\u20136.","journal-title":"Ann Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-16541-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16541-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16541-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T18:02:43Z","timestamp":1792432963000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-16541-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,15]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["16541"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-16541-x","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,15]]},"assertion":[{"value":"13 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki, and the protocol was approved by Institutional Review Board (approval number 260212EXP-02) of Shanghai Proton and Heavy Ion Center. Informed consent was obtained from all the participants. Informed consent to participate was obtained from the parents or legal guardians of any participant under the age of 16: not applicable. All methods were performed in accordance with the relevant guidelines and regulations.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1250"}}